menu
    • menu

    Find Netarsudil manufacturers, exporters & distributors on PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    9

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    0

    NDC API

    NDC API

    0

    VMF

    NDC API

    9

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 377,565

    MARKET PLACE

    4

    API

    0

    FDF

    4INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    1

    FDF Dossiers

    FDF Dossiers

    1

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    7DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    28

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    160,954,924

    Annual Reports

    NA

    Finished Drug Prices

    NA

    36 RELATED EXCIPIENT COMPANIES

    73EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 1254032-66-0, Ar-11324 free base, Rhopressa, Netarsudil [usan], Netarsudil free base, W6i5qdt7qi
    Molecular Formula
    C28H27N3O3
    Molecular Weight
    453.5  g/mol
    InChI Key
    OURRXQUGYQRVML-AREMUKBSSA-N
    FDA UNII
    W6I5QDT7QI
    Netarsudil
    Netarsudil is an amino-isoquinoline amide and inhibitor of Rho kinase (ROCK) and norepinephrine transporter (NET), with potential intraocular pressure (IOP)-lowering activity. Upon ocular administration, netarsudil inhibits ROCK and the Rho pathway, increases aqueous humor (AH) outflow via the trabecular pathway, and lowers IOP. In addition, netarsudil may lower IOP by decreasing episcleral venous pressure and decreasing the production of aqueous humor through inhibition of NET.
    Netarsudil is a Rho Kinase Inhibitor. The mechanism of action of netarsudil is as a Rho Kinase Inhibitor.
    1 2D Structure

    Netarsudil

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate
    2.1.2 InChI
    InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1
    2.1.3 InChI Key
    OURRXQUGYQRVML-AREMUKBSSA-N
    2.1.4 Canonical SMILES
    CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)C(CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C
    2.1.5 Isomeric SMILES
    CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C
    2.2 Other Identifiers
    2.2.1 UNII
    W6I5QDT7QI
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Ar-13324

    2.3.2 Depositor-Supplied Synonyms

    1. 1254032-66-0

    2. Ar-11324 Free Base

    3. Rhopressa

    4. Netarsudil [usan]

    5. Netarsudil Free Base

    6. W6i5qdt7qi

    7. Ar-13324

    8. [4-[(2s)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate

    9. (4-((1s)-1-(aminomethyl)-2-(isoquinolin-6-ylamino)-2-oxoethyl)phenyl)methyl 2,4- Dimethylbenzoate

    10. Benzoic Acid, 2,4-dimethyl-, (4-((1s)-1-(aminomethyl)-2-(6-isoquinolinylamino)-2-oxoethyl)phenyl)methyl Ester

    11. Rhokiinsa

    12. Unii-w6i5qdt7qi

    13. Netarsudil [mi]

    14. Netarsudil [inn]

    15. Netarsudil (usan/inn)

    16. Netarsudil [usan:inn]

    17. Netarsudil [who-dd]

    18. Gtpl9322

    19. Chembl4594250

    20. Schembl16036278

    21. Dtxsid001027774

    22. Bdbm50546247

    23. Zinc113149554

    24. Ar11324

    25. Db13931

    26. Ac-31227

    27. Ar-11324

    28. Ester 60 [pmid: 27072905]

    29. D11030

    30. Q27292390

    2.4 Create Date
    2012-11-30
    3 Chemical and Physical Properties
    Molecular Weight 453.5 g/mol
    Molecular Formula C28H27N3O3
    XLogP34.6
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count8
    Exact Mass453.20524173 g/mol
    Monoisotopic Mass453.20524173 g/mol
    Topological Polar Surface Area94.3 Ų
    Heavy Atom Count34
    Formal Charge0
    Complexity678
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Netarsudil is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

    FDA Label

    Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Aqueous humour flows out of the eye via two pathways: 1) the conventional trabecular pathway and 2) the unconventional uveoscleral pathway. And, although it has been shown that the conventional trabecular pathway accounts for most aqueous outflow due to various pathologies, most medications available for treating glaucoma target the uveoscleral pathway for treatment and leave the diseased trabecular pathway untreated and unhindered in its progressive deterioration and dysfunction. Netarsudil is subsequently a novel glaucoma medication that is both a rho kinase and norepinephrine transport (NATs)s inhibitor that specifically targets and inhibits rho kinase and NATS found in the conventional trabecular pathway while many of its contemporaries offer therapy that focuses on cell and muscle tissue remodelling

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    NETARSUDIL
    5.2.2 FDA UNII
    W6I5QDT7QI
    5.2.3 Pharmacological Classes
    Rho Kinase Inhibitors [MoA]; Rho Kinase Inhibitor [EPC]
    5.3 ATC Code

    S01EX05

    S - Sensory organs

    S01 - Ophthalmologicals

    S01E - Antiglaucoma preparations and miotics

    S01EX - Other antiglaucoma preparations

    S01EX05 - Netarsudil

    5.4 Absorption, Distribution and Excretion

    Absorption

    The systemic exposure of netarsudil and its active metabolite, AR-13503, after topical ocular administration of netarsudil opthalmic solution 0.02% once daily (one drop bilaterally in the morning) for eight days in 18 healthy subjects demonstrated no quantifiable plasma concentrations of netarsudil (lower limit of quantitation [LLOQ] 0.100 ng/mL) post dose on Day 1 and Day 8. Only one plasma concentration at 0.11 ng/mL for the active metabolite was observed for one subject on Day 8 at 8 hours post dose.

    Route of Elimination

    Clinical studies assessing the *in vitro* metabolism of netarsudil using corneal tissue from humans, human plasma, and human liver microsomes and microsomal S9 fractions demonstrated that netarsudil metabolism occurs through esterase activity. Subsequent metabolism of netarsudil's esterase metabolite, AR-13503, was not detectable. In fact, esterase metabolism in human plasma was not detected during a 3 hour incubation.

    Volume of Distribution

    As netarsudil and its active metabolite demonstrate a high degree of protein binding, it is expected to exhibit a low volume of distribution.

    Clearance

    The clearance of netarsudil is strongly influenced by its low plasma concetrations following topical administration and absorption and high protein binding in human plasma inn.

    5.5 Metabolism/Metabolites

    After topical ocular dosing, netarsudil is metabolized by esterases in the eye to its active metabolite, netarsudil-M1 (or AR-13503).

    5.6 Biological Half-Life

    The half-life of netarsudil incubated *in vitro

    with human corneal tissue is 175 minutes.

    5.7 Mechanism of Action

    The medical condition glaucoma is a leading cause of progressive visual impairment and blindness across the world with primary open-angle glaucoma (POAG) being the major type of glaucoma. Elevated intraocular pressure (IOP) resulting from increased resistance to aqueous humor outflow is considered a major risk for the development and progression of POAG, but various clinical studies have demonstrated that the reduction and tight control of IOP can delay or prevent POAG and the vision loss associated with it. Ordinary physiological IOP results from aqueous humor produced by the ocular ciliary body and its outflow through two main outflow pathways: the conventional (trabecular) and the unconventional (uveoscleral) pathways. Under ordinary physiological conditions, diagnostic tracers have shown that the conventional trabecular pathway accounts for up to 90% of aqueous humor outflow. Through this pathway, aqueous humor drains from the anterior chamber sequentially through the uveal and corneoscleral meshwork beams, juxtacanalicular connective tissue (JCT) region, and inner wall (IW) endothelial cells of Schlemm's canal (SC) until finally entering the lumen of SC. From there aqueous humor drains into the collector channels, intravascular plexus, epscleral veins, and finally into the blood circulation. In glaucomatous eyes, elevated IOP is the result of abnormally increased resistance to aqueous outflow in the conventional trabecular pathway due to apparent increases in the contractile tone and stiffness of the trabecular pathway meshwork (TM), changes in extracellular matrix composition, and/or a decrease in the conductance of the IW endothelial cells of SC. Subsequently, as a rho kinase inhibitor, the novelty of netarsudil lies in its ability or specificity to apply its mechanism of action directly and specifically at the diseased TM of the conventional trabecular outflow pathway. In particular, rho kinases are serine/threonine kinases that function as important downstream effectors of Rho GTPase. Such activity in the TM and SC drives actomysin contraction, promotes extracellular matrix production, and increases cell stiffness. Acting as an inhibitor of rho kinase, netarsudil consequently reduces cell contraction, decreases the expression of fibrosis-related proteins, and reduces cell stiffness in the TM and SC cells. As a result, netarsudil has been able to demonstrate increases in trabecular outflow facility, increases in the effective filtration area of the TM, cause expansion of the TM tissue, and dilate episcleral veins. Furthermore, netarsudil is also believed to possess inhibitory action against the norepinephrine transporter (NET). Such inhibition of the NET prevents reuptake of norepinephrine at noradrenergic synapses, which results in an increase in the strength and duration of endogenous norepinephrine signaling. As a consequence of this enhanced signaling, norepinephrine-induced vasoconstriction that can reduce blood flow to the ciliary body may subsequently be responsible for a mechanism in which the formation of aqueous humor may be delayed, prolonged, or reduced as well.

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"NETARSUDIL","year":"2021","qtr":"Q2","strtotime":1621017000,"product":"NETARSUDIL DIMESYLATE","address":"PLOT NO.C-24, MNS HOUSE, INDUSTRIAL ESTATE, SANATH NAGAR,","city":"HYDERABAD, AP.","supplier":"MAITHRI DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"LABORATORIOS POEN S.A.C.I.F.I.","customerCountry":"ARGENTINA","quantity":"0.01","actualQuantity":"10","unit":"GMS","unitRateFc":"2007.5","totalValueFC":"19746.1","currency":"USD","unitRateINR":144639,"date":"15-May-2021","totalValueINR":"1446390","totalValueInUsd":"19746.1","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"1787168","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.C-24, MNS HOUSE, INDUSTRIAL ESTATE, SANATH NAGAR,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"NETARSUDIL MESYLATE","year":"2021","qtr":"Q2","strtotime":1622399400,"product":"NETARSUDIL MESYLATE IH BATCH NO: NET\/21\/001 MFG. DT: APR 2021 RE-TEST DATE: MAR 2022","address":"FLAT B-3\/33 B HIGHWAY VIEW CHS LTD ,JANU COMPOUND KURAR VILLAGE","city":"MALAD EAST MUMBAI,MAHARASHTRA","supplier":"FLAX LABORATORIES","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"MINAPHARM PHARMCEUTICALS AND CHEMIC","customerCountry":"EGYPT","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"217.3","totalValueFC":"4273.8","currency":"USD","unitRateINR":15652.549999999999,"date":"31-May-2021","totalValueINR":"313051","totalValueInUsd":"4273.8","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"2105334","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"FLAT B-3\/33 B HIGHWAY VIEW CHS LTD ,JANU COMPOUND KURAR VILLAGE, MALAD EAST MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1628533800,"product":"NETARSUDIL MESYLATE IH","address":"FLAT B-3\/33 B HIGHWAY VIEW CHS LTD ,JANU COMPOUND KURAR VILLAGE","city":"MALAD EAST MUMBAI,MAHARASHTRA","supplier":"FLAX LABORATORIES","supplierCountry":"INDIA","foreign_port":"GUADALAJARA","customer":"CENTRO DE INVESTIGACION SOPHIA S.A","customerCountry":"MEXICO","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"225.9","totalValueFC":"21942","currency":"USD","unitRateINR":16273.799999999999,"date":"10-Aug-2021","totalValueINR":"1627380","totalValueInUsd":"21942","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"3742956","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MEXICO","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"FLAT B-3\/33 B HIGHWAY VIEW CHS LTD ,JANU COMPOUND KURAR VILLAGE, MALAD EAST MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1635273000,"product":"NETARSUDIL MESYLATE IH-PHARMACEUTICAL AL","address":"FLAT B-3\/33 B HIGHWAY VIEW CHS LTD ,JANU COMPOUND KURAR VILLAGE","city":"MALAD EAST MUMBAI,MAHARASHTRA","supplier":"FLAX LABORATORIES","supplierCountry":"INDIA","foreign_port":"KARACHI -","customer":"ATCO LABORATORIES LTD","customerCountry":"PAKISTAN","quantity":"0.03","actualQuantity":"25","unit":"GMS","unitRateFc":"210","totalValueFC":"5179.4","currency":"USD","unitRateINR":15520,"date":"27-Oct-2021","totalValueINR":"388000","totalValueInUsd":"5179.4","indian_port":"BOMBAY AIR","hs_no":"29333990","bill_no":"5617548","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"FLAT B-3\/33 B HIGHWAY VIEW CHS LTD ,JANU COMPOUND KURAR VILLAGE, MALAD EAST MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1647369000,"product":"PHARMACEUTICAL RAW MATERIAL- NETARSUDIL","address":"B-29\/1, MIDC MAHAD,,BIRWADI VILLAG E ROAD","city":"MAHAD,MAHARASHTRA","supplier":"FLAX LABORATORIES","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"GLOBAL ADVANCED PHARMACEUTICAL","customerCountry":"EGYPT","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"225","totalValueFC":"4316.5","currency":"USD","unitRateINR":16450,"date":"16-Mar-2022","totalValueINR":"329000","totalValueInUsd":"4316.5","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"8987740","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"B-29\/1, MIDC MAHAD,,BIRWADI VILLAG E ROAD, MAHAD,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669314600,"product":"NETARSUDIL DIMESYLATE","address":"PLOT NO.C-24, MSN HOUSE,,INDUSTRIA L ESTATE, SANATH NAGAR,","city":"HYDERABAD,TELANGANA","supplier":"MAITHRI DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"TO THE ORDER OF,","customerCountry":"BANGLADESH","quantity":"0.00","actualQuantity":"2","unit":"GMS","unitRateFc":"1600","totalValueFC":"3173.5","currency":"USD","unitRateINR":129500,"date":"25-Nov-2022","totalValueINR":"259000","totalValueInUsd":"3173.5","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"5713859","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.C-24, MSN HOUSE,,INDUSTRIA L ESTATE, SANATH NAGAR,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670005800,"product":"NETARSUDIL DIMESYLATE ( NEXIO20006 (MFG","address":"NO 31, RACE COURSE ROAD BANGALORE CONTACT NO: 919945641620","city":"BENGALURU","supplier":"MICRO LABS LIMITED","supplierCountry":"INDIA","foreign_port":"WARSAW","customer":"POLFA WARSZAWA S.A.","customerCountry":"POLAND","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"1000","totalValueFC":"19440.3","currency":"USD","unitRateINR":80100,"date":"03-Dec-2022","totalValueINR":"1602000","totalValueInUsd":"19440.3","indian_port":"BANGALORE AIR","hs_no":"29334100","bill_no":"5918269","productDescription":"API","marketType":"REGULATED MARKET","country":"POLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"NO 31, RACE COURSE ROAD BANGALORE CONTACT NO: 919945641620, BENGALURU","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1672857000,"product":"PHARMACEUTICAL RAW MATERIAL- NETARSUDIL","address":"B-29\/1, MIDC MAHAD,,BIRWADI VILLAG E ROAD","city":"MAHAD,MAHARASHTRA","supplier":"FLAX LABORATORIES","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"WORLD MEDICINE","customerCountry":"TURKEY","quantity":"0.02","actualQuantity":"18","unit":"GMS","unitRateFc":"250","totalValueFC":"4488.8","currency":"USD","unitRateINR":20388.888888888891,"date":"05-Jan-2023","totalValueINR":"367000","totalValueInUsd":"4488.8","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"6724952","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"B-29\/1, MIDC MAHAD,,BIRWADI VILLAG E ROAD, MAHAD,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1693938600,"product":"PHARMACEUTICAL RAW MATERIAL -NETARSUDILMESYLATE IH BATCH NO. - NET\/22\/002 MFG DT. OCT, 2022, RETEST DT. SEP, 2025","address":"PLOT NO.B-29\/1 MIDC","city":"MAHAD","supplier":"FLAX LABORATORIES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TAEJOON PHARMACEUTICAL CO. LTD.","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.00","actualQuantity":"3","unit":"GMS","unitRateFc":"330","totalValueFC":"975.8","currency":"USD","unitRateINR":27000,"date":"06-Sep-2023","totalValueINR":"81000","totalValueInUsd":"975.8","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"3753750","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT NO.B-29\/1 MIDC, MAHAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1693938600,"product":"PHARMACEUTICAL RAW MATERIAL -NETARSUDILMESYLATE IH BATCH NO. - NET\/22\/003 MFG DT. NOV, 2022, RETEST DT.OCT, 2025","address":"PLOT NO.B-29\/1 MIDC","city":"MAHAD","supplier":"FLAX LABORATORIES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TAEJOON PHARMACEUTICAL CO. LTD.","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.00","actualQuantity":"3","unit":"GMS","unitRateFc":"330","totalValueFC":"975.8","currency":"USD","unitRateINR":27000,"date":"06-Sep-2023","totalValueINR":"81000","totalValueInUsd":"975.8","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"3753750","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT NO.B-29\/1 MIDC, MAHAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725474600,"product":"PHARMACEUTICAL RAW MATERIAL -NETARSUDILMESYLATE IH. BATCH NO.-NET\/24\/001 MFG DT.-MAY, 2024 RETEST DT. APR-2027","address":"PLOT NO.B-29\/1 MIDC","city":"MAHAD","supplier":"FLAX LABORATORIES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"SHAHJALAL ISLAMI BANK ","customerCountry":"BANGLADESH","quantity":"0.05","actualQuantity":"50","unit":"GMS","unitRateFc":"250","totalValueFC":"12204.5","currency":"USD","unitRateINR":20455,"date":"05-Sep-2024","totalValueINR":"1022750","totalValueInUsd":"12204.5","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"3773000","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT NO.B-29\/1 MIDC, MAHAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726165800,"product":"NETARSUDIL DIMESYLATE IH BATCH NO. NEXIO23002 (MFG DATE 07.2023- EXP DATE 12.2026)PO 16360624-120 DT 26.06.2024","address":"NO 31, RACE COURSE ROAD,BANGALORE","city":"BENGALURU,KARNATAKA","supplier":"MICRO LABS LIMITED","supplierCountry":"INDIA","foreign_port":"RIJEKA","customer":"JADRAN GALENSKI LABORATORIJ D D","customerCountry":"CROATIA","quantity":"0.15","actualQuantity":"0.15","unit":"KGS","unitRateFc":"250000","totalValueFC":"37208.6","currency":"USD","unitRateINR":20787499.866666667,"date":"13-Sep-2024","totalValueINR":"3118124.98","totalValueInUsd":"37208.6","indian_port":"Bangalore Air","hs_no":"29334100","bill_no":"3979630","productDescription":"API","marketType":"REGULATED MARKET","country":"CROATIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"NO 31, RACE COURSE ROAD,BANGALORE, BENGALURU,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1730917800,"product":"NETARSUDIL 2,4-DIMETHYLBENZOIC ACID IMP(QTY: 100 MG)","address":"PLOT NO.C-24, MNS HOUSE,","city":"HYDERABAD, AP.","supplier":"MAITHRI DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"JEDDAH","customer":"JAMJOOM PHARMACEUTICALS FACTORY","customerCountry":"SAUDI ARABIA","quantity":"0.00","actualQuantity":"0.1","unit":"GMS","unitRateFc":"40000","totalValueFC":"3943.7","currency":"USD","unitRateINR":3327998.8999999999,"date":"07-Nov-2024","totalValueINR":"332799.89","totalValueInUsd":"3943.7","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"5410558","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"SAUDI ARABIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.C-24, MNS HOUSE,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731004200,"product":"NETARSUDIL DIMESYLATE IH ( BATCH NO: NEXIO22001 ) ( KG ) ( QTY- 0.010 )","address":"NO 31, RACE COURSE ROAD,BANGALORE","city":"BENGALURU,KARNATAKA","supplier":"MICRO LABS LIMITED","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"EVA PHARMA","customerCountry":"EGYPT","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"275000","totalValueFC":"2646.9","currency":"USD","unitRateINR":22336783,"date":"08-Nov-2024","totalValueINR":"223367.83","totalValueInUsd":"2646.9","indian_port":"Bangalore Air","hs_no":"29334100","bill_no":"5452033","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"NO 31, RACE COURSE ROAD,BANGALORE, BENGALURU,KARNATAKA","customerAddress":""}]
    15-May-2021
    08-Nov-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business

    Details:

    Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical candidates.


    Lead Product(s): Netarsudil,Latanoprost

    Therapeutic Area: Ophthalmology Brand Name: Rocklatan

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Alcon Inc

    Deal Size: $930.0 million Upfront Cash: Undisclosed

    Deal Type: Acquisition December 22, 2022

    blank

    01

    Alcon Inc

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed

    Alcon Inc

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Netarsudil,Latanoprost

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Alcon Inc

    Deal Size : $930.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic P...

    Details : Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmace...

    Product Name : Rocklatan

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    December 22, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business

    Details:

    Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease.


    Lead Product(s): Netarsudil,Latanoprost

    Therapeutic Area: Ophthalmology Brand Name: Rocklatan

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Alcon Inc

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition November 22, 2022

    blank

    02

    Alcon Inc

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed

    Alcon Inc

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Netarsudil,Latanoprost

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Alcon Inc

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic P...

    Details : Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye di...

    Product Name : Rocklatan

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    November 22, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio

    Details:

    Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical candidates.


    Lead Product(s): Netarsudil,Latanoprost

    Therapeutic Area: Ophthalmology Brand Name: Rocklatan

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Alcon Inc

    Deal Size: $930.0 million Upfront Cash: Undisclosed

    Deal Type: Acquisition August 22, 2022

    blank

    03

    Alcon Inc

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed

    Alcon Inc

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Netarsudil,Latanoprost

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Alcon Inc

    Deal Size : $930.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio

    Details : Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmace...

    Product Name : Rocklatan

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    August 22, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, ...

    Details:

    Rocklatan (netarsudil and latanoprost), indicated for reduction of elevated IOP in patients with glaucoma or ocular hypertension, demonstrated consistent IOP reduction of ~9.5 mmHg and an average IOP reduction of 37% from baseline in European Phase 3B clinical trial.


    Lead Product(s): Netarsudil

    Therapeutic Area: Ophthalmology Brand Name: Rocklatan

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 20, 2022

    blank

    04

    Alcon Inc

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed

    Alcon Inc

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Netarsudil

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive S...

    Details : Rocklatan (netarsudil and latanoprost), indicated for reduction of elevated IOP in patients with glaucoma or ocular hypertension, demonstrated consistent IOP reduction of ~9.5 mmHg and an average IOP reduction of 37% from baseline in European Phase 3B cl...

    Product Name : Rocklatan

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    April 20, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions

    Details:

    Santen will be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Rhopressa and Rocklatan.


    Lead Product(s): Netarsudil

    Therapeutic Area: Ophthalmology Brand Name: Rhopressa

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Santen Pharmaceutical

    Deal Size: $168.0 million Upfront Cash: $88.0 million

    Deal Type: Expanded Collaboration December 07, 2021

    blank

    05

    Alcon Inc

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed

    Alcon Inc

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Netarsudil

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Santen Pharmaceutical

    Deal Size : $168.0 million

    Deal Type : Expanded Collaboration

    DEALS_DEV arrow-down

    Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe ...

    Details : Santen will be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Rho...

    Product Name : Rhopressa

    Product Type : Small molecule

    Upfront Cash : $88.0 million

    December 07, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360

    Details:

    THC-VHS-NEC (SBI-100) + Rhopressa® (netarsudil) a Rho-Kinase Inhibitor combination , Produces Superior IOP Lowering Activity.THCVHS a synthetic molecule, developed to treat glaucoma.


    Lead Product(s): 9-delta-Tetrahydrocannabinol-valine-hemisuccinate,Netarsudil

    Therapeutic Area: Ophthalmology Brand Name: THC-VHS

    Study Phase: PreclinicalProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 21, 2021

    blank

    06

    Skye Bioscience

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed

    Skye Bioscience

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 9-delta-Tetrahydrocannabinol-valine-hemisuccinate,Netarsudil

    Therapeutic Area : Ophthalmology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists ...

    Details : THC-VHS-NEC (SBI-100) + Rhopressa® (netarsudil) a Rho-Kinase Inhibitor combination , Produces Superior IOP Lowering Activity.THCVHS a synthetic molecule, developed to treat glaucoma.

    Product Name : THC-VHS

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    October 21, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries

    Details:

    Santen will look after sales, marketing and pricing decisions relating to Rhopressa® and Rocklatan®. Aerie and Santen will collaborate for the first Phase 3 study for Rhopressa® in Japan.


    Lead Product(s): Netarsudil

    Therapeutic Area: Ophthalmology Brand Name: Rhopressa

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Santen Pharmaceutical

    Deal Size: $149.0 million Upfront Cash: $50.0 million

    Deal Type: Licensing Agreement October 28, 2020

    blank

    07

    Alcon Inc

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed

    Alcon Inc

    U.S.A
    arrow
    Biotech Digital Meet
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Netarsudil

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Santen Pharmaceutical

    Deal Size : $149.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and...

    Details : Santen will look after sales, marketing and pricing decisions relating to Rhopressa® and Rocklatan®. Aerie and Santen will collaborate for the first Phase 3 study for Rhopressa® in Japan.

    Product Name : Rhopressa

    Product Type : Small molecule

    Upfront Cash : $50.0 million

    October 28, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Topical

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    ABOUT THIS PAGE

    Looking for 1254032-66-0 / Netarsudil API manufacturers, exporters & distributors?

    Netarsudil manufacturers, exporters & distributors 1

    73

    PharmaCompass offers a list of Netarsudil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Netarsudil manufacturer or Netarsudil supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Netarsudil manufacturer or Netarsudil supplier.

    PharmaCompass also assists you with knowing the Netarsudil API Price utilized in the formulation of products. Netarsudil API Price is not always fixed or binding as the Netarsudil Price is obtained through a variety of data sources. The Netarsudil Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Netarsudil

    Synonyms

    1254032-66-0, Ar-11324 free base, Rhopressa, Netarsudil [usan], Netarsudil free base, W6i5qdt7qi

    Cas Number

    1254032-66-0

    Unique Ingredient Identifier (UNII)

    W6I5QDT7QI

    About Netarsudil

    Netarsudil is an amino-isoquinoline amide and inhibitor of Rho kinase (ROCK) and norepinephrine transporter (NET), with potential intraocular pressure (IOP)-lowering activity. Upon ocular administration, netarsudil inhibits ROCK and the Rho pathway, increases aqueous humor (AH) outflow via the trabecular pathway, and lowers IOP. In addition, netarsudil may lower IOP by decreasing episcleral venous pressure and decreasing the production of aqueous humor through inhibition of NET.

    Netarsudil Manufacturers

    A Netarsudil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Netarsudil, including repackagers and relabelers. The FDA regulates Netarsudil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Netarsudil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Netarsudil manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Netarsudil Suppliers

    A Netarsudil supplier is an individual or a company that provides Netarsudil active pharmaceutical ingredient (API) or Netarsudil finished formulations upon request. The Netarsudil suppliers may include Netarsudil API manufacturers, exporters, distributors and traders.

    click here to find a list of Netarsudil suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Netarsudil GMP

    Netarsudil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Netarsudil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Netarsudil GMP manufacturer or Netarsudil GMP API supplier for your needs.

    Netarsudil CoA

    A Netarsudil CoA (Certificate of Analysis) is a formal document that attests to Netarsudil's compliance with Netarsudil specifications and serves as a tool for batch-level quality control.

    Netarsudil CoA mostly includes findings from lab analyses of a specific batch. For each Netarsudil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Netarsudil may be tested according to a variety of international standards, such as European Pharmacopoeia (Netarsudil EP), Netarsudil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Netarsudil USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search